PART I Overview We are a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. MASH was previously known as nonalcoholic steatohepatitis (NASH). MASH is the leading cause of liver transplantation in women, the second leading cause of all liver transplantation ...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001628280-26-009514 | EDGAR | 84K words |
| 2025-02-26 | 2024-12-31 | 0001628280-25-007980 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001628280-24-007376 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001193125-23-045575 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001193125-22-051569 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001193125-21-056164 | EDGAR | — |
| 2020-02-26 | 2019-12-31 | 0001193125-20-049021 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001047469-19-000725 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001047469-18-001557 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001047469-17-002260 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001628280-25-048559 | EDGAR | 22K words |
| 2025-08-05 | 2025-06-30 | 0001628280-25-037613 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001628280-25-021356 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001628280-24-044445 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001628280-24-035400 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001628280-24-020865 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001193125-23-270803 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001193125-23-205535 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001193125-23-138863 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001193125-22-276468 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001193125-22-211757 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001193125-22-144674 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-19 | 0001628280-26-009476 | EDGAR | 2K words |
| 2026-01-30 | 0001104659-26-008698 | EDGAR | — |
| 2025-12-11 | 0001628280-25-056533 | EDGAR | — |
| 2025-11-04 | 0001628280-25-048525 | EDGAR | — |
| 2025-08-05 | 0001628280-25-037596 | EDGAR | — |
| 2025-07-30 | 0001104659-25-071928 | EDGAR | — |
| 2025-07-22 | 0001628280-25-035506 | EDGAR | — |
| 2025-06-20 | 0001628280-25-032358 | EDGAR | — |
| 2025-05-01 | 0001628280-25-021314 | EDGAR | — |
| 2025-04-17 | 0001628280-25-018242 | EDGAR | — |
286 total filings indexed. 254 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001157601 |
| Ticker | MDGL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.madrigalpharma.com |
| Listed | 2007-02-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report